Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.
Loretta G QueZhonghui YangNjira L LugogoRohit K KatialSteven A ShoemakerJanice M TrohaDavid M RodmanRobert M TigheMonica KraftPublished in: Immunity, inflammation and disease (2018)
In this early phase exploratory proof of concept trial in asthma, N6022 did not significantly alter methacholine PC20 FEV1 at 24 h, but did have a treatment effect at 7 days compared to baseline. Further investigation of the efficacy of S-nitrosoglutathione reductase inhibition in a patient population with eosinophilic asthma is warranted.